

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA ISOTOPE & RADIATION CORPORATION**

**中國同輻股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1763)**

### **ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024**

#### **ANNUAL RESULTS**

The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of China Isotope & Radiation Corporation (the “**Company**” or “**CIRC**”, together with its subsidiaries, the “**Group**” or “**we**”) is pleased to announce the consolidated financial statements of the Group for the year ended 31 December 2024 (“**2024**” or the “**Reporting Period**”) audited by SHINEWING (HK) CPA Limited, the Company’s auditor, together with the comparative figures for the same period of 2023, as follows:

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS**  
**for the year ended 31 December 2024**  
*(Expressed in Renminbi (“RMB”))*

		<b>2024</b>	<b>2023</b>
	<i>Notes</i>	<b><i>RMB’000</i></b>	<b><i>RMB’000</i></b>
Revenue	4	<b>7,574,756</b>	6,634,992
Cost of sales		<b>(3,891,924)</b>	(3,152,753)
<b>Gross profit</b>		<b>3,682,832</b>	3,482,239
Other income, gains and losses	5	<b>77,518</b>	240,928
Selling and distribution expenses		<b>(1,623,621)</b>	(1,768,368)
Administrative expenses		<b>(704,520)</b>	(635,914)
Research and development costs		<b>(300,286)</b>	(306,051)
Impairment losses on trade and other receivables		<b>(45,541)</b>	(71,236)
<b>Profit from operations</b>		<b>1,086,382</b>	941,598
Finance costs	6(a)	<b>(48,423)</b>	(36,142)
Share of profits less losses of associates		<b>(14,088)</b>	(14,303)
Share of profits of joint ventures		<b>21,353</b>	31,284
<b>Profit before taxation</b>	6	<b>1,045,224</b>	922,437
Income tax expense	7	<b>(165,687)</b>	(146,307)
<b>Profit for the year</b>		<b>879,537</b>	776,130
<b>Attributable to:</b>			
Equity shareholders of the Company		<b>406,645</b>	370,967
Non-controlling interests		<b>472,892</b>	405,163
<b>Profit for the year</b>		<b>879,537</b>	776,130
<b>Earnings per share:</b>	8		
Basic and diluted (RMB)		<b>1.27</b>	1.16

# CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

for the year ended 31 December 2024

(Expressed in RMB)

	2024 <i>RMB'000</i>	2023 <i>RMB'000</i>
<b>Profit for the year</b>	<b>879,537</b>	776,130
<b>Other comprehensive (expense) income for the year (after tax and reclassification adjustments)</b>		
Items that will not be reclassified to profit or loss:		
Remeasurement of net defined benefit liability	(14,645)	(621)
Equity investments at FVOCI-net movement in fair value reserve (non-recycling)	<u>10,606</u>	<u>(5,185)</u>
<b>Other comprehensive expense for the year</b>	<b>(4,039)</b>	(5,806)
<b>Total comprehensive income for the year</b>	<b><u>875,498</u></b>	<u>770,324</u>
<b>Attributable to:</b>		
Equity shareholders of the Company	406,256	365,070
Non-controlling interests	<u>469,242</u>	<u>405,254</u>
<b>Total comprehensive income for the year</b>	<b><u>875,498</u></b>	<u>770,324</u>

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION****At 31 December 2024***(Expressed in RMB)*

		<b>31 December 2024</b>	<b>31 December 2023</b>
	<i>Notes</i>	<b><i>RMB'000</i></b>	<b><i>RMB'000</i></b>
<b>Non-current assets</b>			
Property, plant and equipment		<b>4,328,121</b>	3,601,172
Investment properties		<b>49,566</b>	46,053
Intangible assets		<b>320,363</b>	212,117
Goodwill		<b>81,526</b>	81,526
Interests in associates		<b>93,415</b>	119,599
Interests in joint ventures		<b>477,453</b>	503,514
Long-term receivables		<b>51,148</b>	49,196
Unquoted equity investments		<b>162,545</b>	156,394
Deferred tax assets		<b>284,922</b>	220,431
Other non-current assets		<b>–</b>	7,239
		<b>5,849,059</b>	4,997,241
<b>Current assets</b>			
Inventories		<b>787,185</b>	814,165
Contract assets		<b>58,787</b>	19,862
Trade and bill receivables	<i>10</i>	<b>4,922,128</b>	3,876,341
Deposits and other receivables		<b>294,677</b>	254,569
Prepayments		<b>206,171</b>	337,908
Cash at bank and on hand		<b>2,649,354</b>	2,891,624
		<b>8,918,302</b>	8,194,469
<b>Current liabilities</b>			
Bank loans		<b>940,725</b>	196,310
Trade payables	<i>11</i>	<b>791,481</b>	626,668
Accruals and other payables		<b>3,097,491</b>	3,255,920
Lease liabilities		<b>26,023</b>	20,879
Provisions		<b>92,084</b>	86,612
Income tax payable		<b>75,577</b>	67,532
<b>Total current liabilities</b>		<b>5,023,381</b>	4,253,921
<b>Net current assets</b>		<b>3,894,921</b>	3,940,548
<b>Total assets less current liabilities</b>		<b>9,743,980</b>	8,937,789

	<b>31 December 2024 RMB'000</b>	31 December 2023 RMB'000
<b>Non-current liabilities</b>		
Bank loans	<b>1,049,474</b>	1,447,011
Corporate bonds	<b>499,287</b>	–
Deferred income	<b>123,322</b>	59,779
Lease liabilities	<b>52,728</b>	31,322
Defined benefit retirement obligation	<b>55,125</b>	44,007
Deferred tax liabilities	<b>7,625</b>	8,876
Provisions	<b>153,800</b>	139,728
Other long-term payables	<b>58,024</b>	67,738
	<hr/>	<hr/>
<b>Total non-current liabilities</b>	<b>1,999,385</b>	1,798,461
	<hr/>	<hr/>
<b>Net assets</b>	<b>7,744,595</b>	7,139,328
	<hr/>	<hr/>
<b>Capital and reserves</b>		
Share capital	<b>319,875</b>	319,875
Reserves	<b>4,685,426</b>	4,373,445
	<hr/>	<hr/>
<b>Total equity attributable to equity shareholders of the Company</b>	<b>5,005,301</b>	4,693,320
<b>Non-controlling interests</b>	<b>2,739,294</b>	2,446,008
	<hr/>	<hr/>
<b>Total equity</b>	<b>7,744,595</b>	7,139,328
	<hr/>	<hr/>

## 1. STATEMENT OF COMPLIANCE

These consolidated financial statements have been prepared in accordance with all applicable International Financial Reporting Standards (“IFRSs”), which collective term includes all applicable individual International Financial Reporting Standards, International Accounting Standards (“IASs”) and Interpretations issued by the International Accounting Standards Board (“IASB”) and the applicable disclosure requirements of the Hong Kong Companies Ordinance. These consolidated financial statements also comply with the applicable disclosure provisions of the Rules Governing the Listing of Securities on the Stock Exchange. Material accounting policies adopted by the Group are disclosed below.

The IASB has issued certain new and amendments to IFRSs that are first effective or available for early adoption for the current accounting period of the Group. Note 3 provides information on any changes in accounting policies resulting from initial application of these developments to the extent that they are relevant to the Group for the current accounting periods and reflected in these consolidated financial statements.

## 2. BASIS OF PREPARATION OF THE CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements for the year ended 31 December 2024 comprise the Group and the Group’s interests in associates and joint ventures.

The measurement basis used in the preparation of the consolidated financial statements is the historical cost basis except that the equity investments are stated at their fair value.

The preparation of consolidated financial statements in conformity with IFRSs requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

## 3. CHANGES IN ACCOUNTING POLICIES

In the current year, the Group has applied, for the first time, the following amendments to IFRSs issued by the IASB which are effective for the Group’s financial year beginning on 1 January 2024:

Amendments to IFRS 16	Lease Liability in a Sale and Leaseback
Amendments to IAS 1	Classification of Liabilities as Current or Non-current
Amendments to IAS 1	Non-current Liabilities with Covenants
Amendments to IAS 7 and IFRS 7	Supplier Finance Arrangements

Except as described below, the application of the amendments to IFRSs in the current year has had no material impact on the Group’s financial positions and performance for the current and prior years and/or on the disclosures set out in these consolidated financial statements.

**Impact on application of Amendments to IAS 1 Classification of Liabilities as Current or Non-current (the “2020 Amendments”); and Amendments to IAS 1 – Non-current Liabilities with Covenants (the “2022 Amendments”)**

The 2020 Amendments clarify the requirements on determining if a liability is current or non-current, in particular the determination over whether an entity has the right to defer settlement of the liability for at least 12 months after the reporting period. The amendments specify that an entity’s right to defer settlement must exist at the end of the reporting period. Classification is unaffected by management’s intentions or expectations about whether the entity will exercise its right to defer settlement. The amendments also clarify the classification of liabilities that will or may be settled by issuing an entity’s own equity instruments.

The 2022 Amendments further clarify that, among covenants of a liability arising from a loan arrangement, only those with which an entity must comply on or before the reporting date affect the classification of that liability as current or non-current. Additional disclosures are required for non-current liabilities that are subject to the entity complying with future covenants within 12 months after the reporting period.

Upon application of the amendments, the Group has reassessed the terms and conditions of its loan arrangements. The adoption of the amendments has no material impact on the classification of the Group’s liabilities as at 1 January 2023, 31 December 2023 and 31 December 2024.

#### **4. REVENUE AND SEGMENT REPORTING**

##### **(a) Revenue**

The Group is principally engaged in research, development, manufacturing and sale of a broad range of nuclear medicines (formerly known as pharmaceuticals) and radioactive source products, also design, manufacturing, construction and installation of gamma ray irradiation facilities, provision of irradiation service for sterilisation purpose, technical services, sales of medical devices and sale of nuclear medical equipment (formerly known as radiation therapy equipment).

##### **(i) Disaggregation of revenue**

Disaggregation of revenue from contracts with customers by major products or service lines is as follows:

	2024 RMB’000	2023 RMB’000
<b>Revenue from contracts with customers within the scope of IFRS 15</b>		
Disaggregated by major products of service lines		
– sales of nuclear medicines	4,167,606	4,017,476
– sales of radioactive source products	632,822	532,567
– sales of nuclear medical equipment	912,477	706,124
– sales of medical device	801,650	544,690
– sales of nucleic acid detection kit	–	111,107
– irradiation services	172,788	161,687
– technical services	552,522	349,390
– revenue from construction contracts	67,706	35,826
– others	267,185	176,125
	<b>7,574,756</b>	<b>6,634,992</b>

Disaggregation of revenue from contracts with customers by the timing of revenue recognition is disclosed in Note 4(b).

The Group’s customer base is diversified and there is no customer with whom transactions have exceeded 10% of the Group’s revenue in 2024 and 2023.

**(ii) *Revenue expected to be recognised in the future arising from contracts with customers in existence at the reporting date.***

As at 31 December 2024, the aggregated amount of the transaction price allocated to the remaining performance obligations under the Group's existing contracts is approximately RMB31,550,000 (2023: RMB19,862,000). This amount mainly represents revenue expected to be recognised in the future from construction contracts entered into by the customers with the Group. The Group will recognise the expected revenue in future when or as the work is completed, which is expected to occur within the next 12 months.

The Group has applied the practical expedient in paragraph 121 of IFRS 15 to its sales contracts such that the above information does not include information about revenue that the Group will be entitled to when it satisfies the remaining performance obligations under the sales contracts that had an original expected duration of one year or less.

The above amount also does not include any amounts of completion bonuses that the Group may earn in the future by meeting the conditions set out in the Group's construction contracts with customers, unless at the reporting date it is highly probable that the Group will satisfy the conditions for earning those bonuses.

**(b) *Segment reporting***

The Group manages its businesses by divisions, which are mainly organised by business lines (products and services). In a manner consistent with the way in which information is reported internally to the Group's most senior executive management for the purposes of resource allocation and performance assessment, the Group has presented the following five reportable segments. No operating segments have been aggregated to form the following reportable segments.

- Nuclear medicines: manufacturing and sale of a range of imaging diagnostic and therapeutic radio pharmaceuticals imaging, UBT diagnostic kits and test analyzers and other products.
- Radioactive source products: sale of medical and industrial radioactive source products and technical services.
- Irradiation: provision of irradiation services to manufacturers of medical facilities, pharmaceuticals, cosmetics and food in the PRC for sterilization purposes, and also design, manufacturing and installation of gamma ray irradiation facilities to irradiation service providers and technical services.
- Nuclear medical equipment and related services: sale of nuclear medical equipments and provision of related maintenance services.
- Other businesses: provision of a full range of services for the users, including services such as trade services for nuclear technology industry applications, medical product applications, technical services and sales of medical devices.

**(i) *Segment results, assets and liabilities***

For the purposes of assessing segment performance and allocating resources among segments, the Group's senior executive management monitors the results attributable to each reportable segment on the following basis:

Revenue and expenses are allocated to the reportable segments with reference to revenue generated by those segments and the expenses incurred by those segments. The measure used for reporting segment profit is gross profit. The Group's other income and expense items, and assets and liabilities, are not measured under individual segments. Accordingly, no information on segment assets and liabilities are presented.



Disaggregation of revenue from contracts with customers by timing of revenue recognition, as well as information regarding the Group's reportable segments as provided to the Group's most senior executive management for the purposes of resource allocation and assessment of segment performance for the years ended 31 December 2024 and 2023 is set out below.

	Year ended 31 December 2024					Total RMB'000
	Nuclear medicines RMB'000	Radioactive source products RMB'000	Irradiation RMB'000	Nuclear medical equipment and related services RMB'000	Other businesses RMB'000	
<b>Disaggregated by timing of revenue recognition</b>						
Point in time	4,167,606	716,082	172,788	912,476	1,096,566	7,065,518
Over time	-	-	12,270	310,485	186,483	509,238
<b>Revenue from external customers</b>	4,167,606	716,082	185,058	1,222,961	1,283,049	7,574,756
Inter-segment revenue	3,462	29,730	15,275	8,420	22,783	79,670
<b>Reportable segment revenue</b>	<b>4,171,068</b>	<b>745,812</b>	<b>200,333</b>	<b>1,231,381</b>	<b>1,305,832</b>	<b>7,654,426</b>
<b>Reportable segment profit (gross profit)</b>	<b>2,919,778</b>	<b>318,962</b>	<b>101,774</b>	<b>223,130</b>	<b>138,880</b>	<b>3,702,524</b>
	Year ended 31 December 2023					Total RMB'000
	Nuclear medicines RMB'000	Radioactive source products RMB'000	Irradiation RMB'000	Nuclear medical equipment and related services RMB'000	Other businesses RMB'000	
<b>Disaggregated by timing of revenue recognition</b>						
Point in time	4,128,583	586,207	161,687	706,406	720,814	6,303,697
Over time	-	-	9,108	227,337	94,850	331,295
<b>Revenue from external customers</b>	4,128,583	586,207	170,795	933,743	815,664	6,634,992
Inter-segment revenue	3,681	51,869	7,760	6,969	819	71,098
<b>Reportable segment revenue</b>	<b>4,132,264</b>	<b>638,076</b>	<b>178,555</b>	<b>940,712</b>	<b>816,483</b>	<b>6,706,090</b>
<b>Reportable segment profit (gross profit)</b>	<b>2,892,901</b>	<b>276,405</b>	<b>91,433</b>	<b>167,287</b>	<b>84,557</b>	<b>3,512,583</b>

**(ii) Reconciliations of reportable segment profit (gross profit)**

	<b>2024</b> <b>RMB'000</b>	<b>2023</b> <b>RMB'000</b>
Reportable segment profit (gross profit)	<b>3,702,524</b>	3,512,583
Elimination of inter-segment profit (gross profit)	<b>(19,692)</b>	(30,344)
Consolidated gross profit	<b>3,682,832</b>	<b>3,482,239</b>

**(iii) Geographic information**

All of the Group's operations are carried out and most of the Group's customers are located in the PRC. The Group's non-current assets, including property, plant and equipment, investment properties, lease prepayments and intangible assets are all located or allocated to operations located in the PRC.

**5. OTHER INCOME, GAINS AND LOSSES**

	<b>2024</b> <b>RMB'000</b>	<b>2023</b> <b>RMB'000</b>
Bank interest income	<b>29,617</b>	30,973
Government grants	<b>50,592</b>	32,626
Dividend income on unquoted equity investments	<b>4,470</b>	5,593
Rental and related income from operating leases	<b>787</b>	1,281
Gain on early termination of a lease	<b>160</b>	—
Technical services income	<b>9,097</b>	7,560
Net foreign exchange loss	<b>(9,438)</b>	(4,387)
Net loss on disposal of property, plant and equipment	<b>(197)</b>	(135)
Loss on disposal of an associate	<b>(19,337)</b>	—
Gain on disposal of a subsidiary	<b>—</b>	158,435
Gain on deemed disposal of a subsidiary	<b>—</b>	124
Others	<b>11,767</b>	8,858
	<b>77,518</b>	<b>240,928</b>

## 6. PROFIT BEFORE TAXATION

Profit before taxation is arrived at after charging/(crediting):

### (a) Finance costs

	2024 <i>RMB'000</i>	2023 <i>RMB'000</i>
Interests on bank loans	52,551	32,439
Interests on corporate bonds	2,172	–
Less: interest expense capitalised into construction progress	<u>(16,429)</u>	<u>(9,606)</u>
	38,294	22,833
Interests on discounted bills	9	–
Interests on lease liabilities	2,650	3,231
Interests accretion on reclamation obligations, net	5,850	6,592
Interests cost on defined benefit retirement plans	1,218	1,316
Interests cost on long-term payables	<u>402</u>	<u>2,170</u>
	<u><b>48,423</b></u>	<u><b>36,142</b></u>

The borrowing costs have been capitalised at 2.82% (2023: 3.57%) per annum.

### (b) Staff costs

	2024 <i>RMB'000</i>	2023 <i>RMB'000</i>
Salaries, wages and other benefits	791,391	775,565
Contributions to defined contribution retirement plans	93,714	90,994
Expenses recognised in respect of defined benefit retirement plans	<u>919</u>	<u>819</u>
	<u><b>886,024</b></u>	<u><b>867,378</b></u>

Employees of the Company's subsidiaries in the PRC are required to participate in a defined contribution retirement scheme administered and operated by the local municipal government. The Company's subsidiaries in the PRC contribute funds which are calculated on certain percentages of the average employee salary as agreed by the local municipal government to the scheme to fund the retirement benefits of the employees.

(c) **Other items**

	2024 RMB'000	2023 RMB'000
Depreciation		
– property, plant and equipment	217,920	226,476
– investment properties	6,562	6,194
Amortisation		
– intangible assets ( <i>Note (i)</i> )	20,397	20,895
Impairment losses recognised		
– trade and bill receivables	29,541	67,099
– contract assets	2,363	1,317
– deposits and other receivables	16,000	4,137
Auditors' remuneration		
– audit services	1,950	1,950
– non audit services	43	299
Increase in provisions for reclamation obligations	13,994	1,353
Cost of inventories ( <i>Note (ii)</i> )	3,687,920	2,960,107

*Notes:*

- (i) Amortisation of intangible assets is included in cost of sales, selling and distribution expenses, research and development costs, administrative expenses and capitalised to inventories of approximately RMB2,307,000 (2023: RMB1,496,000), RMB1,013,000 (2023: RMB502,000), RMB4,797,000 (2023: RMB5,330,000), RMB12,280,000 (2023: RMB13,567,000) and RMB143,000 (2023: RMB158,000) respectively.
- (ii) Cost of inventories includes approximately RMB454,128,000 (2023: RMB400,818,000) relating to staff costs, depreciation and amortisation expenses, which are also included in the respective total amounts disclosed separately above or in Note 6(b) for each of these types of expenses.

**7. INCOME TAX**

Taxation in the consolidated statement of profit or loss represents:

	2024 RMB'000	2023 RMB'000
<b>Current tax</b>		
Provision for the year	204,580	153,002
Under-provision in respect of prior years	27,789	13,825
	232,369	166,827
<b>Deferred tax</b>		
Origination and reversal of temporary differences	(66,682)	(20,520)
	165,687	146,307

## 8. EARNINGS PER SHARE

The calculation of basic earnings per share is based on the profit attributable to ordinary equity shareholders of the Company of approximately RMB406,645,000 (2023: RMB370,967,000) and the weighted average of 319,874,900 ordinary shares (2023: 319,874,900 ordinary shares).

The Company did not have any potential dilutive shares in existence during the years ended 31 December 2024 and 2023. Accordingly, diluted earnings per share is the same as basic earnings per share.

## 9. DIVIDENDS

### (i) Dividends payable to equity shareholders of the Company attributable to the year

	2024 <i>RMB'000</i>	2023 <i>RMB'000</i>
Final dividend proposed after the end of the reporting period of RMB30.9 cents per ordinary share (2023: RMB31.31 cents per ordinary share)	<u>98,841</u>	<u>100,153</u>
Interim dividend proposed after the end of the interim period, of RMB7.24 cents per ordinary share (2023: nil)	<u>23,159</u>	<u>—</u>

The final dividend proposed after the end of the reporting period has not been recognised as a liability at the end of the reporting period.

### (ii) Dividends payable to equity shareholders of the Company attributable to the previous financial year, approved and paid during the year

	2024 <i>RMB'000</i>	2023 <i>RMB'000</i>
Final dividend in respect of the previous financial year, approved and paid during the year, of RMB31.31 cents per share (2023: RMB44.07 cents per share)	<u>100,153</u>	<u>140,969</u>

### (iii) Dividends payable to equity shareholders of the Company attributable to the current interim period, approved and paid during the year

	2024 <i>RMB'000</i>	2023 <i>RMB'000</i>
Interim dividend in respect of the current interim period, approved and paid during the year, of RMB7.24 cents per share (2023: nil)	<u>23,159</u>	<u>—</u>

## 10. TRADE AND BILL RECEIVABLES

	2024 <i>RMB'000</i>	2023 <i>RMB'000</i>
Bill receivables	105,453	111,870
Trade receivables due from		
– Related parties under CNNC	67,432	62,626
– associates and joint ventures	23,676	19,872
– third parties	4,958,561	3,886,629
	5,155,122	4,080,997
Less: loss allowance for expected credit loss	(232,994)	(204,656)
	<b>4,922,128</b>	<b>3,876,341</b>

As at 31 December 2024, the gross amount of trade receivables arising from contracts with customers amounted to approximately RMB5,155,122,000 (31 December 2023: RMB4,080,997,000).

### Aging analysis

The aging analyses of trade and bill receivables, based on the invoice dates and net of loss allowance, are as follows:

	2024 <i>RMB'000</i>	2023 <i>RMB'000</i>
Within 1 year	4,164,294	3,335,766
1 to 2 years	589,784	389,000
2 to 3 years	122,553	115,870
Over 3 years	45,497	35,705
	<b>4,922,128</b>	<b>3,876,341</b>

The Group granted credit term on a case by case basis and trade and bills receivables are required to be settled in accordance with credit terms as stipulated in the contract and invoice due to issuance.

## 11. TRADE PAYABLES

	2024 <i>RMB'000</i>	2023 <i>RMB'000</i>
Trade payables due to		
– related parties under CNNC	43,974	44,384
– associates and joint ventures	4,920	5,879
– third parties	742,587	576,405
	<u>791,481</u>	<u>626,668</u>
	<b><u>791,481</u></b>	<b><u>626,668</u></b>

### (a) Aging analysis

As of the end of the reporting period, the aging analyses of trade payables, based on the invoice dates, are as follows:

	2024 <i>RMB'000</i>	2023 <i>RMB'000</i>
Within 1 year	597,314	573,437
1 to 2 years	170,032	37,684
2 to 3 years	15,281	2,803
over 3 years	8,854	12,744
	<u>791,481</u>	<u>626,668</u>
	<b><u>791,481</u></b>	<b><u>626,668</u></b>

All of the trade payables are usually for settlement within one year or are repayable on demand.

## MANAGEMENT DISCUSSION AND ANALYSIS

Focusing on the two major industrial directions of nuclear healthcare and irradiation application, the Group is committed to providing integrated solutions for nuclear medicine and radiotherapy, as well as radiation technology promotion and application, forming a “6+N” industrial layout with six major businesses as the core, including nuclides, nuclear medicines, nuclear medical equipment, integrated solution for nuclear medicine, radioactive source and application, and irradiation application. The Group is primarily engaged in the research, development, manufacturing and sale of nuclides, diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications, the provision of irradiation service for sterilization purpose, material modification and engineering, procurement and construction (“EPC”) service for the design, manufacturing and installation of irradiation facilities and the provision of nuclear medical equipment and construction service of nuclear medicine department to hospitals and other medical institutions.

### BUSINESS REVIEW

For the year ended 31 December 2024, we operated five business segments, namely nuclear medicines (formerly known as pharmaceuticals), radioactive source products, irradiation, nuclear medical equipment and related services (formerly known as radiation therapy equipment and related services) and other businesses. In 2024, we continued to intensify our market development efforts and achieved continued growth in economic efficiency. For the year of 2024, we recorded revenue of RMB7,574.8 million, representing a year-on-year increase of 14.2%, realised net profit of RMB879.5 million, representing a year-on-year increase of 13.3%, with net profit attributable to the parent company achieving RMB406.6 million, representing a year-on-year increase of 9.6%.

### BUSINESS SEGMENTS

#### **1. Nuclear medicines**

The Group is a leading manufacturer of diagnostic and therapeutic radiopharmaceuticals in China, primarily engaged in the research, development, manufacturing and sale of a wide range of imaging diagnostic and therapeutic radiopharmaceuticals, Urea Breath Test (UBT) kits and analyzers in the domestic market.

During the Reporting Period, the Group adhered to the strategic development plan of each business segment. In respect of nuclear medicines segment, it provided a stable supply of radiopharmaceuticals to domestic medical institutions and continuously promoted development in existing industries and businesses, while accelerating the research, development and launch of new products. In September 2024, it obtained the drug registration certificate for sodium fluorine-<sup>18</sup> injection, which is the first PET imaging agent approved for bone imaging in China, filling the market gap of PET diagnostic imaging agent in the field of bone imaging in China. This year, the negotiated price of national medical insurance was officially implemented for the therapeutic sodium iodine-<sup>131</sup> capsule, meeting the clinical needs of more patients. The Group continued to carry out marketing of respiratory disease testing products and promote academic brand building, and participated in a total of 59 important academic conferences in the industry during the Reporting Period, which enhanced its brand influence and market penetration. In addition, the Company continued to empower public welfare, and carried out more than 700 public welfare activities during the Reporting Period, demonstrating the responsibility and commitment of central enterprise with a high sense of responsibility. Its subsidiary, Zhonghe Headway, won the 2023 China Medical Equipment “National Brand Gold Award” (民族品牌金獎) and “Excellent National Brand Award” (優秀民族品牌獎).



During the Reporting Period, the Group recorded RMB4,167.6 million in revenue from sales of nuclear medicines, representing a year-on-year increase of 0.9%, recorded RMB1,751.5 million in revenue from imaging diagnostic and therapeutic radiopharmaceuticals, representing a year-on-year increase of 4.1%, and the layout of the pharmaceutical center began to take effect, and the revenue of technetium marked drugs increased by 8.7% year-on-year. In terms of breath test, it continued to maintain a stable high market share, and recorded RMB2,349.5 million in revenue, representing a year-on-year increase of 1.1%.

## **2. *Radioactive source products***

The Group is a major manufacturer of medical and industrial radioactive source products in China and also a radioactive source producer with a most complete range of radioactive source product offerings in China, primarily engaged in the research, development, manufacturing and sale of various medical and industrial radioactive sources products as well as provision of related technical services.

During the Reporting Period, gamma knife source and non-destructive testing radioactive source continued to maintain a stable and high market share. CNNC Qinshan Isotope successfully obtained the Class A radiation safety license, and the cobalt-60 radioactive source production line delivered 2 million curies. The installation of equipment was completed in the first phase of the Jiajiang radioactive source base, and the roofing of main structure was completed in the second phase. The supporting radioactive sources developed for the “Shenzhou XVII” manned spacecraft contributed to its successful return, thus guaranteeing the success of China’s manned spacecraft mission.

During the Reporting Period, the Group recorded RMB716.1 million in revenue from radioactive source products, representing a year-on-year increase of 22.2%, mainly due to the significant growth of industrial sources, of which the revenue of radiation sources was RMB234.3 million, representing a year-on-year increase of 69.3%; the revenue of the startup neutron sources was RMB121.9 million, representing a year-on-year increase of 65.6%.

## **3. *Irradiation***

In the field of irradiation processing, the Group mainly aimed at providing the manufacturers of medical devices, food, traditional Chinese medicine and cosmetics for sterilization in China, meanwhile, EPC services related to the design, manufacturing and installation of irradiation facilities were also accessible.

During the Reporting Period, the Group made efforts deeply in the traditional irradiation market and actively explored the market for new irradiation products. BINE High-Tech Co., Ltd., a subsidiary of the Group, undertook the construction of CIRC’s BINA irradiation center project in Bangladesh located in Dhaka, Bangladesh, which was the first major international project of CIRC in the field of irradiation application of nuclear technology in Bangladesh.

During the Reporting Period, the Group recorded RMB185.1 million in revenue from irradiation-related business, representing a year-on-year increase of 8.4%.

#### 4. Nuclear medical equipment and related services

During the Reporting Period, the Group accelerated domestic manufacturing process of high-end radiotherapy equipment. The new generation of Precision radiation therapy planning system was successfully approved for medical device registration certificate. In July 2024, the world's first spiral tomotherapy system, Tomo C, was delivered to Shandong Cancer Hospital (山東省腫瘤醫院) for installation, and Tomo C was successfully selected into the 2024 high-end medical equipment promotion and application project of two ministries and commissions (Ministry of Industry and Information Technology/National Health Commission) and Tianjin First (Set) Major Technical Equipment Promotion and Application Guidance Catalog (Version 2024) (《天津市首台(套)重大技術裝備推廣應用指導目錄》(2024 版)), with sales during the year leading in the domestic market. The “R&D of Spiral Tomography System Beam Subsystem” was completed with the key task ahead of schedule and successfully passed the acceptance of technical indicators.

In addition, the project “Development of Smart Cobalt-60-based Cone Beam Focused Stereotactic Therapy System” obtained the medical device registration certificate, with 3 units sold during the year, realizing fully independent “resource and equipment” synergies.

During the Reporting Period, the Group recorded RMB1,223.0 million in revenue from nuclear medical equipment and related services, representing a year-on-year increase of 31.0%.

#### 5. Other businesses

In order to provide users with a full range of services, the Group also provides trade and other services in relation to nuclear technology industry applications and medical product applications. We primarily provide users with trade services in relation to imported radioactive source, medical nuclides, imported radiopharmaceuticals, nuclear instruments and devices, medical equipment and other products. The Group is promoting the cooperation with international pharmaceutical companies to introduce advanced radiopharmaceuticals, intensive management services for hospital consumables, and import agency sales of medical devices. During the Reporting Period, new products such as the scarce medical isotope Tb-161 were introduced, filling the gaps in many domestic markets and providing a strong guarantee for the research and development of new radiopharmaceuticals in China.

During the Reporting Period, revenue from trade services and other businesses of the Group was RMB1,283.0 million, representing a year-on-year increase of 57.3%.

The table below sets forth our revenue by business segment in 2024 and 2023:

(RMB in million, except for percentage)	Year ended 31 December 2024		Year ended 31 December 2023	
	Amount	%	Amount	%
Nuclear medicines	4,167.6	55.0	4,128.6	62.2
Radioactive source products	716.1	9.5	586.2	8.8
Irradiation	185.1	2.4	170.8	2.6
Nuclear medical equipment and related services	1,223.0	16.1	933.7	14.1
Other businesses	1,283.0	17.0	815.7	12.3
Total	<u>7,574.8</u>	<u>100.0</u>	<u>6,635.0</u>	<u>100.0</u>

## Marketing

During the Reporting Period, the Group continued to promote brand building and marketing. In November 2024, the Group, as the main organizer, released five innovative transformation results at the “Nuclear Technology Application Industry Chain Co-chain Action Conference” (核技術應用產業鏈共鏈行動大會) held in Chengdu, Sichuan. During the Reporting Period, the Group participated in the annual academic meeting of the Nuclear Medicine Branch of the Chinese Medical Association and held a seminar on the new quality productivity of nuclear medicine; participated in the International Nuclear Industry Exhibition, Medical Equipment Expo and other exhibitions, to fully demonstrate the industry status of CIRC as the industry driver of the nuclear technology application.

The Group continued to promote the reform of its sales model and promote the synergistic, high-quality and safe development of breath testing products, radioactive drugs, radioactive sources and radiotherapy equipment. In order to promote the implementation of the “Healthy China Strategy”, the Group and the Nuclear Medicine Branch of the Chinese Medical Association jointly launched a demonstration project for the promotion of nuclear medicine diagnosis and treatment, and a total of 11 nuclear medicine demonstration projects in primary hospitals were completed during the Reporting Period, helping the development of nuclear medicine at the grassroots level.

## International Business

During the Reporting Period, the Group robustly explored the international market and exported breath test kits, radiopharmaceuticals, radioactive source, medical equipment and devices as well as other products to dozens of countries and regions such as Brazil, Peru, Nigeria, Colombia, Ecuador, Indonesia, Vietnam, Bangladesh, Singapore and Thailand, realizing a total export revenue of RMB626.5 million. International business revenue from regular medical products maintained significant growth in 2024.

During the Reporting Period, the Group made breakthroughs in a number of international businesses. Among them, the irradiation station project of Bangladesh Nuclear Agricultural Research Institute was successfully signed in 2024, realizing the first irradiation station of overseas government agency and the first overseas EPC project; the overall supply project of nuclear medical equipment in Nigeria was successfully signed, realizing the successful implementation of the Group’s overall nuclear medical equipment supply project for the first time; the layout of the ASEAN market was improved, with the successful export of the cold medicine (冷藥) supporting radiopharmaceuticals to Thailand; and the Group actively explored markets in Latin America, Central Asia, Southeast Asia and other markets, seized opportunities, fulfilled smoothly, completed product shipments, expanded new markets and achieved new growth in export revenue. The Group signed strategic cooperation agreements with a number of Brazilian entities to support the signing of strategic cooperation memorandums of understanding between the National Atomic Energy Agency and Brazil in the field of nuclear technology applications. Negotiations on new projects in Uzbekistan, Russia, Algeria, Malaysia and other countries were progressing in an orderly manner. The Group participated in a number of world-class industry exhibitions and academic conferences, such as the IAEA Ministerial Conference on Nuclear Technology Cooperation and Scientific Applications and the China-ASEAN Seminar on the Peaceful Uses of Nuclear Technology, and released globally three integrated solutions for nuclear technology application at the IAEA, so as to enhance brand awareness and influence in overseas markets. In addition, the Group actively expanded international channels, improved the export risk management mechanism, and promoted the overseas registration of self-produced products to ensure the steady improvement of the level of international operation.

## Scientific Research and Innovation

The Group has always actively conducted research and development work on various types of imaging diagnosis and therapeutic pharmaceuticals to fill gaps in various fields of medical treatment and meet the medical needs of China. On 3 September 2024, sodium fluorine-<sup>18</sup> injection obtained the drug registration certificate from the National Medical Products Administration and was approved for marketing, filling the market gap of PET diagnostic imaging agent in the field of bone imaging in China. On 24 December 2024, fluoropylamide [<sup>18</sup>F] injection (氟[<sup>18</sup>F]吡嗪胺注射液) passed the review of the National Medical Products Administration and was approved for the clinical trial. As of 31 December 2024, we had a number of imaging diagnosis and therapeutic radiopharmaceuticals under research and development. Among them, fluorine-<sup>18</sup> betazine injection has completed Phase I clinical trials, iodine-<sup>131</sup>-MIBG injection, technetium-<sup>99m</sup> sulfide colloidal injection, <sup>68</sup>Ga-Dotatate injection, fluorine-<sup>18</sup> stamine injection and lutetium-<sup>177</sup> oxyoctreotide injection were in Phase III clinical trial, fluorine-<sup>18</sup>-L dopa injection was approved for the clinical trial, and a variety of imaging diagnosis and therapeutic radiopharmaceuticals were in preclinical research and development stage. In addition, the Group actively carried out the layout of isotope and nuclear medicine equipment.

## Patents and awards

During the Reporting Period, the Group achieved remarkable results in intellectual property, with a total of 274 patent applications and 224 patent authorizations. As of 31 December 2024, the Group had 969 valid patents, including 196 invention patents, and its scientific and technological strength has been continuously enhanced. During the Reporting Period, there were 6 registered trademarks, 17 registered copyrights, 4 national defense industry standards, 9 group standards, 3 national standards and 1 agricultural standard being compiled.

In terms of scientific and technological awards and honors, the Preparation Technology of Key Nuclide <sup>64</sup>Cu for the Integration of Diagnosis and Treatment and Research on Related Drugs (《診療一體化關鍵核素 <sup>64</sup>Cu 製備技術及相關藥物研究》) jointly declared by CIRC and HTA Co., Ltd. (原子高科股份有限公司, “HTA”) won the second prize of CNNC Science and Technology Award, and the Key Technology and Application of Nuclide Diagnosis and Treatment for Thyroid Diseases (《甲狀腺疾病核素診療關鍵技術及應用》) won the third prize of Sichuan Medical Science and Technology Award.

## Diagnostic drugs

### *Diagnostic drugs for tumors*

1. Bone imaging drug: sodium fluorine-<sup>18</sup> is a PET bone imaging drug used to diagnose lesions with altered bone activity, including bone metastases, incipient fracture, ostealgia, joint hyperplasia, etc. The Group's product under development, sodium fluorine-<sup>18</sup> injection, was completed with clinical trials, obtained the drug registration certificate of the National Medical Products Administration on 3 September 2024 and was approved for marketing, filling the market gap of PET diagnostic imaging agent in the field of bone imaging in China.

2. Pheochromocytoma diagnostic drug: iodine-<sup>131</sup>-MIBG injection can be used for the diagnosis of neuroendocrine tumors such as pheochromocytoma and neuroblastoma. The Group's product under development, iodine-<sup>131</sup>-MIBG injection, has completed the enrollment of patients in phase III clinical trial, and will provide a new diagnostic method for patients with such rare diseases after its marketing, and early and accurate diagnosis will enable patients to obtain better treatment opportunities.
3. Prostate cancer diagnostic drug: PMSA is an ideal tumor marker for prostate cancer. The development of radioactive targeted PMSA diagnostic (therapeutic) drugs is currently a hot spot of interest that the domestic and foreign radiopharmaceutical companies are concerned about and compete for. The combination of [<sup>18</sup>F]Florastamin and PMSA has a higher specificity and a higher safety profile. The Group has signed a joint development agreement with FutureChem in Korea to obtain the exclusive rights to develop, manufacture and market [<sup>18</sup>F]Florastamin injection in PRC. At present, the Group's product under development, [<sup>18</sup>F]Florastamin injection, is in Phase III clinical trial. It will fill the gap of radiodiagnostic drugs for prostate cancer in China after its marketing, realize independence and controllability, and improve the accessibility of drugs for patients in China.
4. Breast cancer sentinel lymph nodes imaging drug: technetium-<sup>99m</sup> sulfide colloid is the first technetium marked radiocolloid for lymph imaging, which is used for the location and tracing of breast cancer sentinel lymph nodes. The Group's products under development, sulfide colloid kit and technetium-<sup>99m</sup> sulfide colloidal injection, are in Phase III clinical trial, which will benefit breast cancer patients and improve the prognosis of the patients in combination with the corresponding treatment.
5. High melanoma diagnostic drug: fluoropylamide [<sup>18</sup>F] injection (氟[<sup>18</sup>F]吡酰胺注射液) is a positron emission tomography (PET) imaging agent, which can quickly combine with melanoma in vivo, with good specificity and high sensitivity, significantly improve the accuracy of melanoma diagnosis and staging, and provide an accurate basis for clinical treatment decisions. Clinical trial was approved on 24 December and the drug is a Class I innovative drug, which will provide a new solution for the accurate diagnosis of melanoma after its marketing.

### ***Diagnostic drugs for neurodegenerative diseases***

1. Alzheimer (AD) diagnostic drug:  $\beta$ -Amyloid (A $\beta$ ) is an important target for early diagnosis of AD. The development of positron emission tomography (PET) imaging agents with high affinity and selectivity with A $\beta$  protein can realize early non-invasive diagnosis of such disease. [<sup>18</sup>F]Florbetazine injection is an A $\beta$  PET imaging agent jointly developed by the Group and the Key Laboratory of the Ministry of Education for Radiopharmaceuticals of Beijing Normal University, which has independent intellectual property rights and good imaging properties, and is a domestic Class I innovative drug. The Group's product under development, [<sup>18</sup>F]Florbetazine injection, is completed with Phase I clinical trial. In the general environment of an aging society, the drug will produce good social benefits and economic value after its marketing.



2. Parkinsonism diagnostic drug: 6-fluorine-<sup>18</sup>-L dopa injection is used clinically for the diagnosis of nervous system diseases such as parkinsonism, schizophrenia and AD, and has clinical value for early diagnosis of disease, assessment of disease severity and cell transplantation detection. The Group's product under development, 6-fluorine-<sup>18</sup>-L dopa injection, is in the preparation for Phase III clinical trial, and will fill the gap of domestic PET Parkinson's drugs after its marketing.

### **Integrated drug for diagnosis and treatment**

Integrated drug for diagnosis and treatment for neuroendocrine tumor. Internationally, the use of <sup>68</sup>Ga-DOTATATE for PET/CT of neuroendocrine tumor has become the gold standard in imaging. <sup>68</sup>Ga-DOTATATE can also be used to evaluate the treatment effect of patients with neuroendocrine tumor. <sup>177</sup>Lu-DOTATATE is an effective drug in the treatment of neuroendocrine tumor. The Group's products under development, <sup>68</sup>Ga-DOTATATE injection and kits and lutetium-<sup>177</sup> oxyoctreotide injection, are in Phase III clinical trial, which will greatly improve the efficiency of diagnosis and treatment of patients with neuroendocrine tumor after their marketing.

### **Therapeutic drug for tumor**

Palladium-<sup>103</sup> sealed source is an in vivo implant for brachytherapy, suitable for the permanent implantation of solid tumors with low to neutral sensitivity to radiation, both for superficial, intra-thoracic and intra-abdominal solid tumors such as prostate cancer, pancreatic cancer, lung cancer, head and neck cancer, as well as for residual diseases and recurrent tumors after external radiation therapy. The Group's product under development, palladium-<sup>103</sup> sealed source, has completed various pre-clinical studies.

### **Nuclides**

The Group introduced ITM Group's carrier-free lutetium-177 nuclide production technology, built the first domestic production line with an annual output of carrier-free lutetium-<sup>177</sup> chloride solution in ten thousand curies, and officially supplied products to the market. The product indicators met the requirements of the European Pharmacopoeia, and more than 30 domestic customers gave good feedback on the trial, providing domestic raw material guarantee for the development of lutetium-177 therapeutic drugs in China.

### **Nuclear medical equipment**

The Gamma-ray Stereotactic Radiotherapy System (Gamma Knife) developed by the Group is a radiosurgery product integrating IGS image guidance technology and radiotherapy technology, which is suitable for the radiotherapy of head and body solid tumors. The product is equipped with functions such as CBCT image guidance, six-dimensional bed auto-correction, large dose rate, and target area AI auto-sketch. It has the advantages of more accurate positioning, smarter treatment planning and treatment process, and shorter single treatment time. The Group's gamma knife products were successfully approved with a medical device registration certificate on 5 July 2024, providing solutions to the clinical needs of more cancer patients.

## **RESEARCH AND DEVELOPMENT PLATFORM**

### **External platforms**

IAEA Radiopharmaceuticals and Radioactive Sources Collaboration Center  
National Atomic Energy Agency Research and Development Center for Nuclear Technology  
(Radiopharmaceutical Engineering Transformation)  
CNNC Radiopharmaceuticals Engineering and Technology Research Center  
Guangdong Radioactive Isotope-labeled Drugs Engineering Technology Research Center  
Guangdong Stable Isotope Application Engineering Technology Research Center  
Shenzhen Carbon Isotope Application Engineering Technology Research Center  
Technology Center of Anhui Young-Hearty Medical Appliance & Equipment Co., Ltd.  
Beijing Enterprise Technology Center  
Chengdu Enterprise Technology Center  
Sichuan Enterprise Technology Center  
CIRC Branch of Isotope Engineering and Technology Research Center  
Sichuan Radioisotope Engineering and Technology Research Center  
Shanxi Molecular Imaging Technology and Equipment Research and Development and  
Transformation Engineering Research Center  
Key Laboratory of Radiopharmaceuticals Quality Control and Evaluation of Guangdong Medical  
Products Administration  
Shanghai Molecular Imaging Probe Engineering Technology Center  
Zhejiang Engineering Research Center for Isotope Preparation and Application Technology

### **Internal platforms**

Radiopharmaceuticals R&D Center  
Stable Isotope and Breath Test Technology R&D Center  
Radioactive Sources and Application R&D Center  
Irradiation Application Technology R&D Center

In terms of industry-academia-research cooperation, the Group has formed active research cooperation with industry-advantaged research institutes, universities and hospitals such as National Institute of Metrology, Shanghai Institute of Materia Medica of Chinese Academy of Sciences, China Institute of Atomic Energy, China Institute for Radiation Protection, Harbin Institute of Technology, Sichuan University, Beijing Normal University, Peking Union Medical College Hospital and 301 Hospital, and strengthened academic exchanges and research talent cultivation through the establishment of joint laboratories, research and development centers, collaborative innovation centers and innovation unions for purpose of achieving comprehensive cooperation in technological innovation.

The Group has a long-standing commitment to building a system of high-level talents, with 1 top foreign talent, 9 national-level talents, 11 provincial and ministerial level talents, 2 chief experts, 10 technology leaders, and a scientific research team of 507 research and development personnel focusing on extensive researching and optimizing production technologies, developing new products and upgrading safety and efficacy existing products to jointly promote technological innovation in various industrial fields of the Group. In addition, the Group has set up a post-doctoral research workstation of MOHRSS, a post-doctoral innovation practice base in Shenzhen, a post-graduate workstation for radiopharmaceuticals in Jiangsu Province and a post-graduate workstation for irradiation application in Suzhou University with an aim of actively developing post-doctoral and post-graduate training and continuously strengthening the construction of talent team.

## **Digital transformation**

The Group carried out the "Key Leaders Talk about Digital Transformation" (主要領導談數字化轉型), formulated an industrial software map, compiled analysis report on the status and needs of digital standards, and issued three-year action plan for cyber security and informatization, so as to steer and implement the digital transformation. The Group completed the Nuclear Intellectual Hub ERP (核智樞 ERP) special training, the publicity and implementation of business processes and data standards, completed the implementation and launch of all member units of the ERP human resource and salary related modules, completed the acceptance and launch of the second phase of Good Supply Practice (GSP) system, and promoted 5 affiliated units. 6 units including HTA successfully passed the inspection of the local Food and Drug Administration, further improving the GSP level of radiopharmaceuticals. The Group promoted the construction of the pilot project of Zhonghe Headway intelligent factory, and held a series of lectures on digital factory construction to realize real-time data collection, analysis and utilization of key equipment, and continuously optimize the early warning model. The Group built a factory supply chain system to realize the data connection of the whole production and manufacturing process from order to production and delivery. It promoted the large-scale application of Beidou, HTA and Chengdu Gaotong Isotope Co., Ltd. (CNNC) (成都中核高通同位素股份有限公司, "CNGT") completed the single Beidou application (單北斗應用) of existing transport vehicle positioning terminals, and CNGT completed the promotion of 60% of the intelligent monitoring terminals of Class II testing radioactive source transport source changers (二類探傷源運輸換源器), further improving the level of safety control.



## Capital Operation

During the Reporting Period, the Group newly established a total of 4 subsidiaries and 1 joint venture company.

S/N	Company name	Nature	Investor	Shareholding percentage	Date of establishment	Registered capital (RMB10,000)	Principal businesses
1	CNNC (Jiangsu) Irradiation Technology Co., Ltd. (中核(江蘇)輻照技術有限公司)	Subsidiary	China Isotope & Radiation Corporation	100%	2024-02-27	20,000	Irradiation service for sterilisation
2	CNNC (Yulin) Irradiation Co., Ltd. (中核(玉林)輻照有限公司)	Subsidiary	China Isotope & Radiation Corporation	51%	2024-05-15	5,000	Irradiation service for sterilisation
3	Zhongtong Yinlong (Tianjin) Sterilisation Technology Co., Ltd. (中同銀龍(天津)滅菌技術有限公司)	Subsidiary	China Isotope & Radiation Corporation	35%	2024-04-07	6,000	Irradiation service for sterilisation
4	CNNC (Jilin) New Material Co., Ltd. (中核(吉林)新材料有限公司)	Subsidiary	China Isotope & Radiation Corporation	67%	2024-04-22	5,800	Research, development, production and sales of irradiation modified materials
5	Gansu Hongye Nuclear Technology Co., Ltd. (甘肅弘業核技術有限公司)	Associate	Chengdu Gaotong Isotope Co., Ltd. (CNNC)	10%	2024-12-18	9,500	Production and sales of radioactive isotope

As of 31 December 2024, the Company's actual amount paid to Tongfu Innovation Industrial Investment Fund Partnership (Limited Partnership) ("**Tongfu Fund**") was RMB410 million (including recovery of principal), accounting for 45.08% of the total actual amount paid to Tongfu Fund, which was RMB910 million. After evaluation, as of 31 December 2024, the net asset of Tongfu Fund measured at fair value was RMB1,007.17 million, and the value of the Company's share of Tongfu Fund's net asset was RMB432.80 million, accounting for 2.93% of the Group's total assets. In 2024, the Company's investment income in Tongfu Fund was RMB1.24 million, and the Company received dividend of RMB4.80 million.

As the main body of the development of the nuclear technology application industry of CNNC, CIRC is responsible for the development of China's nuclear technology application industry. Upholding the strategic objective of "Becoming Larger, Stronger and Better", the Company firmly follows the development concept of "Assetization and Globalization" to transform itself into a topnotch international organization and provider of nuclear technology application products and services. The Company closely focuses on the established strategy and implements the M&A strategy of investment control source, strengthening the core, and expanding applications. The acquisition work and direction focus on the fields such as nuclear medicines, nuclear medical equipment, irradiation applications, and mergers and acquisitions have been carried out in combination with strategic or market investment considerations of different targets. In order to promote the implementation of the Company's strategy, open up new economic growth points, and enhance the Company's economic scale and efficiency, Tongfu Fund completed the second round of fundraising at the end of 2020, and introduced the National Military Civilian Integration Industry Investment Fund Co., Ltd. (國家軍民融合產業投資基金有限責任公司) and Beijing Daxing Development Guidance Fund (Limited Partnership) (北京市大興發展引導基金(有限合伙)), which further enhanced the financial advantages of Tongfu Fund. Tongfu Fund mainly invests in nuclear technology applications such as nuclide manufacturing, radioactive sources, other diagnostic and therapeutic drugs in the field of nuclear medicines application, medical devices, in vitro diagnostics, medical services and industrial irradiation applications.

## **Production Capacity and Base Construction**

In order to meet the people's growing demand for radiopharmaceuticals, in 2024, we accelerated the national layout of pharmaceutical centers, promoted the construction of bases, and enhanced the Company's production capacity in the fields of radiopharmaceuticals, breath diagnostic products, radioactive sources, and irradiation services.

During the Reporting Period, the national network layout of pharmaceutical centers continued to expand. Fuzhou Pharmaceutical Center was completed and put into operation, as a result of which, the cumulative number of centers in operation reached 27. Lanzhou positron drugs production line was completed and put into operation, as a result of which, the cumulative number of companies that can supply positron drugs amounted to 23. 5 pharmaceutical centers have entered the production certification stage, 3 were under construction and 6 were in the pre-project phase, and the network layout of national pharmaceutical centers was becoming more and more perfect. In recent years, the newly planned North China, East China and South China medical base projects have been constructed in an orderly manner, and the North China and East China medical base projects have been completed and passed the completion acceptance, and the South China medical base project has completed land acquisition and geological exploration and entered the feasibility study stage.

The Group continued to strengthen the construction of bases in the fields of nuclear healthcare and irradiation technology application. The high-abundance  $^{13}\text{CO}$  gas enrichment construction project (phase I) passed the completion acceptance of the project, making China the second country in the world with a high-abundance  $^{13}\text{CO}$  gas production capacity of more than 100 kilograms and filling the domestic gap. The first phase of the Jiajiang radioactive source R&D and production base project completed the installation of process equipment, and the second phase completed the roofing of main structure. CNGT's first domestic production line with an annual output of 10,000 curies-level carrier-free lutetium- $^{177}$  and the production line with an annual production capacity of 1,000 germanium-gallium [ $^{68}\text{Ge}$ - $^{68}\text{Ga}$ ] generators were fully completed and put into operation, marking that China officially has the production and supply capacity of two medical nuclides such as 10,000 curies-level lutetium- $^{177}$  and gallium- $^{68}$ , and realizes the domestic large-scale commercial supply. Qinshan isotope production base project completed the installation of process equipment, passed the completion acceptance and obtained the radiation safety license. The cobalt-60 radioactive source production line delivered products with 2 million curies. Tianjin irradiation project obtained construction permit, and after the completion of the project, the Company will further improve the layout of the irradiation industry in the Bohai Rim region, and enhance the Company's market share and technological innovation capabilities in the field of irradiation sterilization.

### **Implementing the “Healthy China” Strategy and Facilitating the Construction of “One County, One Department”**

The Group adheres to the market-oriented, continuously improving its core competitiveness, implementing the “Healthy China” strategy, seizing the historical development opportunities, and taking advantage of the momentum to provide hospital users with integrated solutions for nuclear medicine and radiotherapy. In order to facilitate the implementation of the “Medium and Long-term Development Plan for Medical Isotopes (2021-2035)” (《醫用同位素中長期發展規劃(2021-2035 年)》) and the national development strategy of “One County, One Department”, the Group has established a nuclear medicine development center in a timely manner. Starting from national and provincial demonstration centers and gradually expanding to municipal and county demonstration bases, the Company promotes standardized, regulated, and intelligent department construction solutions across the country, providing six full-cycle intelligent services covering intelligent department planning and design, intelligent site protection construction, intelligent equipment support, nuclear medicines supply and intelligent management, full-process intelligent department management, and expert think-tanks and talent cultivation, thereby contributing to hierarchical diagnosis and treatment, realizing “early screening”, “early diagnosis”, and “early treatment” of severe diseases (tumors) and improving the level of precision medicine in China.

### **Intelligent leadership, demonstration and promotion, and creating a new benchmark for intelligent nuclear medicine demonstration**

In 2024, the Group deepened its cooperation with Peking Union Medical College Hospital to promote the transformation of “industry, academia, research and medicine” achievements. Based on the clinical needs of the department, the team carried out R&D and innovation, overcame difficulties and had the courage to innovate, completing the development and launch of the industry's first, independent and innovative “Irradiation Intelligence 1.0” (輻智 1.0) intelligent nuclear medicine system in just one year, and taking the lead in establishing the world's first national smart nuclear medicine demonstration center in Peking Union Medical College Hospital. The completion of the pilot deployment of the 1.0 system in three hospitals marked a pioneering breakthrough in the construction and operation management of the normalization, systematization, visualization and standardization of nuclear medicine in China, setting a new benchmark for the intelligent and high-quality development of nuclear medicine in China.

Based on the Internet of Things (IoT) architecture, the “Irradiation Intelligence 1.0” (輻智 1.0) intelligent nuclear medicine system is an intelligent IoT system that integrates intelligent IoT equipment, whole-process management of patient visits, clinical diagnosis and treatment process and radiopharmaceuticals quality control process management, protection and environmental monitoring management and department management visualization control platform. Its innovative functions have reached the industry-leading level, which can bring more convenient medical services to patients, provide effective monitoring and quality control methods for the safety of nuclear medicine clinical applications, help departments improve their daily radiation safety management capabilities that meet the requirements of national environmental protection and health supervision standards, help departments reduce costs and increase efficiency, and provide a strong guarantee for precision medical quality control and accurate quantitative diagnosis and treatment.

By the end of 2024, strategic cooperation agreements have been signed with the first batch of 8 demonstration hospitals in China in respect with the “Irradiation Intelligence 1.0” (輻智 1.0) intelligent nuclear medicine overall solution. In terms of independent intellectual property rights, by the end of 2024, 4 invention patents, 1 utility model patent and 7 software copyrights have been intended to apply for the innovation achievements related to the “Irradiation Intelligence 1.0” (輻智 1.0) intelligent nuclear medicine system, of which 1 invention patent and 1 utility model patent have been accepted, and 3 software copyrights have been authorized.

The Group continued to promote the strategic cooperation with the Nuclear Medicine Branch of the Chinese Medical Association to jointly promote the construction of a demonstration base for the advancement of nuclear medicine diagnostic and treatment work in the country, and to help primary hospitals to realize high-quality development through free expert diagnosis, clinical seminars and departmental assistance. By the end of 2024, we started a total of 80 demonstration bases construction projects and had 32 demonstration bases passed the acceptance test and established.

### **Jointly build a nuclear medicine development ecosystem through overall coordination and cooperation alliance**

In February 2024, the Group assisted the Health Commission of Panzhihua City, Sichuan Province to establish the Panxi Nuclear Medicine Specialist Alliance (攀西地區核醫學專科聯盟) that was led by Panzhihua Central Hospital, signed cooperation agreements of Nuclear Medicine Specialist Alliance with seven city-level and county-level tertiary hospitals in Panzhihua, and held the “Training Project for the Construction of Nuclear Medicine Departments in Southwest Sichuan and Northwest Yunnan” at the same time to promote the training of nuclear medicine professionals and promote the high-quality and coordinated development of nuclear medicine in surrounding hospitals.

In March 2024, the Group, together with the Guangdong Provincial Development and Reform Commission, the Department of Science and Technology, the Health Commission and other relevant departments, held the “Expert Seminar on the Preparation of the Guangdong Nuclear Medical R&D and Application Alliance” (廣東省核醫療研發應用聯盟籌備專家研討會) in Guangzhou, where expert representatives from 8 leading hospitals and production and R&D enterprises in Guangdong Province gathered together to discuss the alliance construction plan, promote the establishment of an industry academic exchange and achievement transformation platform integrating government, industry, academia, research, medicine and application, and promote the implementation of “one county, one department” of nuclear medicine innovative R&D and application and intelligent nuclear medicine in Guangdong Province.

In December 2024, the Group, together with 9 tertiary general hospitals in Hainan Province, established the “Hainan Nuclear Medicine Specialist Alliance” (海南省核醫學專科聯盟) in Hainan, established the first provincial intelligent nuclear medicine demonstration center in Hainan Hospital of the PLA General Hospital (解放軍總醫院海南醫院), and held a training course on the construction of the nuclear medicine department in Hainan Free Trade Port at the same time, so as to help the cultivation and improvement of nuclear medicine talents and departments in Hainan, and accelerate the high-quality development and promotion of the intelligent nuclear medicine department.

## **Quality and Safety**

In 2024, the Group closely adhered to the theme of “overall coordination to accumulate strength, excellent performance to promote strong nuclear” (整體協同聚合力卓越績效促強核), was committed to the quality policy of “quality first, customer satisfaction, continuous improvement, pursuit of excellence” (質量第一, 顧客滿意, 持續改進, 追求卓越) and the quality concept of “brand cornerstone, get it right once” (品牌基石、一次做對), and promoted quality in an all-round and multi-dimensional way. The Group deepened the construction of the quality management system. The digital transformation of quality has taken a solid step to build a penetrating quality information system throughout the whole Group to empower management. The Group actively promoted the priority of excellent performance management model, and completed the publicity and training of excellent performance evaluation standards throughout the Group. The Group promoted a number of Lean Six Sigma (精益六西格瑪) Green Belt and Black Belt projects, and some projects have achieved annual cost savings of more than RMB1 million. Mass quality activities have achieved fruitful results, winning several national awards of QC group and quality trustworthy team. With the help of effective management theory, the quality of products and quality management level have been comprehensively improved, and projects such as post-market changes and drug storage at room temperature have been completed, and quality risk has been effectively controlled in the process of quality and efficiency improvement and high-quality development.



In 2024, the Group comprehensively coordinated safety and development, and made concerted progress, and there were no production safety accidents and environmental pollution incidents throughout the year. 18 member units of the Company have successfully passed the on-site review of safety production standardization, and the normalization and standardization level of enterprise safety production management has been effectively improved. We have carried out a three-year special action to tackle the root causes of production safety, built a radiation safety management system of “full scope, whole process and full cycle”, and realized a significant change in radiation safety management “from the surface to the center”. Through innovative measures such as the reuse of waste radioactive sources, both the number and activity of temporarily stored radioactive sources have decreased year-on-year, which has effectively promoted the reduction and recycling of radioactive waste. The first “Radiation Safety Cup”(辐安杯) safety competition was held to promote learning through competition, focusing on improving radiation monitoring, radiation emergency response and compliance awareness, and effectively enhancing employees’ safety skills and emergency response capabilities. We continued to carry out “pairing” activities, actively explore feasible ways to apply advanced safety management tools to nuclear technology application enterprises, integrate the safety concept of “pursuit of excellence” into all aspects of the Company’s management, inject new vitality into safety management, and promote the safety management level to a new level.

## **Future Development**

2025 will mark the 70th anniversary of the founding of nuclear industry in China, and is the final year for realization of the objectives of the “14th Five-Year Plan”. Looking back at the past 40 years of hard work, CIRC has grown from scratch, from small to large, step by step to become the industry leader, and made positive contributions to the nuclear industry’s strong foundation, leapfrog development, overall improvement of system capability, and accelerating catch-up from big to strong. Looking ahead, CIRC will adhere to the principle of “helping people’s livelihood and benefiting society”, give full play to the unique advantages of nuclear medicine in the diagnosis and treatment of major diseases such as neurodegenerative diseases, cardiovascular and cerebrovascular diseases and malignant tumors, and provide quality products, services and integrated solutions to better protect people’s lives and health and facilitate the construction of “Healthy China”.

In 2025, the Company will closely focus on the goals and tasks of the “14th Five-Year Plan”, keep a firm understanding of the profound connotation of “Chinese-style modernization is the greatest politics, and high-quality development is the absolute principle in the new era”, focus on the “needs of the country” and the improvement of “five values”, and promote stable growth, strong innovation and reform with the “eight efforts”, strengthen technological innovation consistently, improve the modern industrial system, accelerate the cultivation and development of new quality productivity, and continuously strengthen our core functions and enhance our core competitiveness, aim at the goal, work hard, pursue excellence and move forward bravely, go all out to win the decisive battle and win the successful conclusion of the “14th Five-Year Plan” of CIRC to lay a solid foundation for the good start of the “15th Five-Year Plan”.

**Firstly, connect up and down, and focus on strengthening strategic leadership.** The Company will deeply analyze the new stage characteristics of the “15th Five-Year Plan” period, solidly carry out the summary and assessment of the “14th Five-Year Plan” and the research on and preparation for the “15th Five-Year Plan”, and scientifically determine the development goals. In addition, we will plan major strategic tasks and projects. The Company will make greater efforts to lay out strategic emerging industries and future industries, and strive to develop new quality productivity. The Company will make efforts to promote professional operation operation, further plan and subdivide the key responsibilities of the segments, further rationalize the production and management relations, and accelerate the cultivation of market entities with combat effectiveness.

**Secondly, forward-looking layout, focusing on promoting scientific and technological innovation.** The Company will establish a market-oriented scientific and technological innovation system, promote the high-level operation of platforms such as the IAEA Collaborative Center for Radiopharmaceuticals and Radioactive Sources (IAEA 放射性藥物及放射源協作中心) and the Nuclear Technology (Radiopharmaceutical) Engineering Transformation Center of the National Atomic Energy Agency (國家原子能機構核技術(放射性藥物)工程轉化中心), optimize the “1+N” operation mode of the CIRC Research Institute (中國同輻研究院), reconstruct the irradiation technology R&D center, and prepare to build a nuclear medical equipment R&D center. We will accelerate the layout of a number of forward-looking scientific research projects, innovate the introduction mode of drug pipelines, and promote capital operation in the field of nuclear medicines. The Company will solidly carry out the planning and application of centralized R&D and basic R&D projects such as AI+ radiopharmaceuticals R&D data model. The Company will accelerate the clinical trials of  $^{68}\text{Ga}$ -DOTATATE injection and other medicines. We will strive for the approval of the SPECT stand-alone machine for marketing, complete the SPECT/CT prototype test and carry out clinical trials.

**Thirdly, seek progress while maintaining stability, and focus on deeply making efforts in existing business.** We will continue to strengthen the construction of a customer-oriented service system and an efficient and collaborative marketing system, and comprehensively improve market coverage and penetration. We will go all out to achieve stable growth in extra-group market for key products in the fields of isotopes and products, nuclear medical equipment, etc., and highlight the market development and scale improvement of key products such as Cyberknife and Tomo C. We will continue to strengthen the reform of the sales model and further reduce the sales rate. We will expand the application of results of high-abundance carbon monoxide gas projects, realizing the localization of raw materials, greatly reducing the production cost of carbon-13 breath diagnostic reagents, reducing costs and increasing profits.

**Fourthly, strive to work hard and strive to speed up the “going out”.** We will insist on paying equal attention to “going out” and “bringing in”, and build core competitiveness around services, channels and teams. The Company will continue to carry out scientific and technological exchanges and industrial cooperation with Brazil in the field of nuclear technology application, and further promote the implementation of the memorandum of understanding on strategic cooperation between China and Brazil in the field of nuclear technology application. The Company will focus on South America, Southeast Asia, the Middle East, North Africa and countries along “the Belt and Road”, promote the large-scale export of core products such as radiopharmaceuticals and nuclear medical equipment with overall solutions, and strive to build a new world.

**Fifthly, cooperate and focus on strengthening the construction of production capacity.** Qinshan isotope base has been put into full operation. The first phase of the Jiajiang radioactive source base has been put into operation, and the second phase has obtained the radiation safety license. The first phase of the North China Medical Base has obtained the production license and started pilot production. Two production lines of technetium drugs in Xinjiang and Guiyang have been put into operation, and three production lines of positron drugs in Fuzhou, Guiyang and Xinjiang have been put into operation. We have scientifically demonstrated and actively and steadily promoted the preliminary work of the second phase of the high-abundance carbon monoxide gas project, the South China base project, the nuclear medicine center project and the irradiation station project to ensure that Yulin Irradiation is fully put into production. We will step up the demonstration construction and product development of intelligent nuclear medicine, and strengthen the capacity building from project design to project implementation, especially to industrial empowerment. No less than 3 new intelligent nuclear medicine projects have been launched and implemented. We are deeply engaged in key regions such as Sichuan and Chongqing, Xinjiang, Guangdong, Jiangsu and Zhejiang, further promote the nuclear medicine specialist alliance, and enhance the business development of “one county, one department” through multiple channels.

**Sixthly, promote stability through progress and focus on the implementation of capital operation.** We will coordinate technological advancement, market growth and economic feasibility, focus on nuclear medicines, nuclear medical equipment, irradiation applications and other fields, focus on strengthening core technologies, making up for industrial shortcomings, enhancing market competitiveness, expanding market share, appropriately extending the industrial chain, expanding industrial scale, and promoting investment and mergers and acquisitions. We will supplement the funds needed for the development of projects such as CNGT through capital increases. We will strengthen the exit of ineffective investments and accelerate the revitalization of assets. We will improve the ESG indicator system, form a complete working mechanism, establish and improve the investor relations management mechanism, and carry out roadshows, investor research and interviews on a regular basis.

**Seventhly, be upright and innovative, and strive to improve governance efficiency.** We will keep the bottom line of zero accidents of safety, environmental protection and quality, and zero leakage of confidentiality. We have promoted 25 subsidiaries to pass the on-site review of safety production standardization, continued to carry out the investigation and management of major accident hidden dangers, strengthened the control of high-risk operations, and strengthened the monitoring and control of environmental emissions. The Company steadily promotes the construction of pharmaceutical centers and irradiation stations and the standardization of operation and management. The Company promotes the quality management system as “constructed as much as possible”. The Company implements the requirements of refined project management, optimizes and upgrades the project management system, and improves project management capabilities. We have fully implemented 100% coverage of substantive secondary centralized procurement. We comprehensively plan for digital transformation and solidly promote the construction of “digital CIRC”. We promote artificial intelligence projects, and CNGT has completed 100% promotion and application of Beidou intelligent monitoring terminals for key radioactive source containers. We further improve the efficiency of capital use and reduce financing costs.



**Eighthly, establish the new before abolishing the old, and strive to deepen reform in an all-round way.** We continue to improve the corporate governance system based on the Articles of Association. We highlight and strengthen the reform of the market-oriented mechanism, solidly promote the new operation and management responsibility system, and continue to promote the competition for management personnel. We improve the market-oriented employment mechanism and the talent flow mechanism. We improve a more accurate, flexible, standardized and efficient income distribution mechanism, explore excess profit sharing incentives, and make good use of medium and long-term incentive tools such as project dividends, post dividends, project co-investment and equity incentives. We promote the deepening of reform, and strive to become a model of reform of science and technology enterprises and a pioneer of independent innovation.

The “14th Five-Year Plan” is a strategic opportunity period for the development of the nuclear technology application industry. We will closely focus on the objectives of the “14th Five-Year Plan”, unify our ideology and understanding, maintain our strategic determination, practice the “CIRC speed”, make every effort to achieve the successful conclusion of the key tasks of the “14th Five-Year Plan”, and accelerate the establishment of an internationally renowned isotope and radiation technology application products and services supply group.

## **PRINCIPAL RISKS AND UNCERTAINTIES**

The Group’s financial condition, results of operations, and business prospects may be affected by a number of risks and uncertainties directly or indirectly pertaining to the Group’s businesses. To the best of knowledge and belief of the Directors, the Directors consider that the following are the principal risks and uncertainties identified by the Group as at the date of this announcement.

### **Operational Risk**

Operational risk is the risk of loss resulting from inadequate or failed internal processes, people and systems or from external events. Responsibility for managing operational risks basically rests with every function at divisional and departmental levels. Key functions in the Group are guided by their standard operating procedures, limits of authority and reporting framework. The management will identify and assess key operational exposures regularly so that appropriate risk response can be taken.

### **Investment Risk**

Investment risk can be defined as the likelihood of occurrence of losses relative to the expected return on any particular investment. Key concern of investment framework will be balancing risk and return across different investments, and thus risk assessment is a core aspect of the investment decision process. Proper authorization system has been set up and detailed analysis will be made before approving investments. Regular updates on the progress of the investments of the Group would be submitted to the Board.

### **Market Risk**

Market risk is the risk that deteriorates profitability or affects ability to meet business objectives arising from the market competition. The management of the Group manages and monitors these exposures to ensure that appropriate measures are implemented on a timely and effective manner.

## **Interest Rate Risk**

For interest-sensitive products and investments, the Group analyses the interest rate exposure on a dynamic basis and considers managing this risk in a cost-effective manner when appropriate, through variety of means.

## **Liquidity Risk**

Liquidity risk is the potential that the Group will be unable to meet its obligations when they fall due because of an inability to obtain adequate funding or liquidate assets. In managing liquidity risk, the Group monitors cash flows and maintains an adequate level of cash and cash equivalent to ensure the ability to finance the Group's operations and reduce the effects of fluctuation in cash flows.

## **Economic Environment**

Most of the Group's facilities, operations are located in and its revenue derived from mainland China. The Group's results of operations and financial condition therefore depend on the economy of mainland China. Mainland China's economy may experience negative economic developments, and other regional economies may also deteriorate.

The Group also has significant business across the PRC and one of its growth strategies is to expand into new regions. These regions have also been adversely affected by the global economic slowdown and any continued slowdown may have an adverse effect on the Group's existing operations in, and planned expansion into, these regions.

## **FINANCIAL REVIEW**

### **Revenue**

We derived our revenue mainly from five major business segments: (1) nuclear medicine; (2) radioactive source products; (3) irradiation; (4) nuclear medical equipment and related services; and (5) other businesses.

Our revenue increased by 14.2% from RMB6,635.0 million in 2023 to RMB7,574.8 million in 2024, which was mainly due to an increase in revenue from our nuclear medical equipment and related services, radioactive source and other businesses segments.

## **Cost of Sales, Gross Profit and Gross Margin**

Our cost of sales increased by 23.4% from RMB3,152.8 million in 2023 to RMB3,891.9 million in 2024, which was mainly due to a corresponding increase in cost of sales of nuclear medical equipment and related services and other businesses, resulting from the increase in revenue.

Our gross profit increased by 5.8% from RMB3,482.2 million in 2023 to RMB3,682.8 million in 2024 and our gross margin decreased from 52.5% to 48.6%. The increase in gross profit and the decrease in gross margin were primarily due to the relatively significant increase in the revenue of the nuclear medical equipment and related services and other businesses, which had a lower gross margin, pulling down the overall gross margin.

## **Other Income, Gains and Losses**

Our other income decreased by 67.8% from RMB240.9 million in 2023 to RMB77.5 million in 2024, mainly because in the same period last year, the Company obtained investment income from the disposal of Beijing North Institute of Biotechnology Co., Ltd. (北京北方生物技术研究所有限公司), a former subsidiary of the Company, and there were no related matters during the year.

## **Selling and Distribution Expenses**

Our selling and distribution expenses decreased by 8.2% from RMB1,768.4 million in 2023 to RMB1,623.6 million in 2024, mainly due to the decrease in sales service fees as a result of the changes in the Company's nuclear medicines sales policies during the year.

The percentage of our selling and distribution expenses to revenue decreased from 26.7% in 2023 to 21.4% in 2024.

## **Administrative Expenses, Research and Development Costs and Credit Impairment Losses**

Our administrative expenses, research and development costs and credit impairment losses increased by 3.7% from RMB1,013.2 million in 2023 to RMB1,050.3 million in 2024, mainly due to (i) the increase in employee compensation, and (ii) the increase in assets impairment loss during this year.

The percentage of our administrative expenses, research and development costs and credit impairment losses to revenue decreased from 15.3% in 2023 to 13.9% in 2024.

## **Finance Costs**

Our finance costs increased 34.0% from RMB36.1 million in 2023 to RMB48.4 million in 2024, mainly due to the increase in external borrowing for funding needs.

## **Share of Losses of Associates and Share of Profits of Joint Ventures**

Our share of losses of associates decreased by 1.5% from RMB14.3 million in 2023 to RMB14.1 million in 2024, mainly due to the decrease in losses of associates during the year.

Our share of profits of joint ventures decreased by 31.7% from RMB31.3 million in 2023 to RMB21.4 million in 2024, mainly due to the decrease in profits of the joint ventures of the Company.

## **Profit before Tax**

As a result of the foregoing, our profit before tax increased by 13.3% from RMB922.4 million in 2023 to RMB1,045.2 million in 2024.

## **Income Tax Expense**

Our income tax expense increased by 13.2% from RMB146.3 million in 2023 to RMB165.7 million in 2024. Our effective tax rates were both 15.9% in 2023 and 2024.

## **Profit for the Year**

As a result of the foregoing, our profit for the year increased by 13.3% from RMB776.1 million in 2023 to RMB879.5 million in 2024.

## **FINANCIAL POSITION**

### **Overview**

For the year ended 31 December 2024, the total assets of the Group have increased. The total assets, the total liabilities and the total equity were RMB14,767.4 million, RMB7,022.8 million and RMB7,744.6 million, respectively.

## Net Current Assets

The table below sets forth our current assets, current liabilities and net current assets as at the dates indicated:

	<i>RMB in million</i>	
	<b>31 December 2024</b>	31 December 2023
Inventories	<b>787.2</b>	814.2
Contract assets	<b>58.8</b>	19.9
Trade and bill receivables	<b>4,922.1</b>	3,876.3
Deposits and other receivables	<b>294.7</b>	254.6
Prepayments	<b>206.2</b>	337.9
Cash at bank and on hand	<b>2,649.3</b>	2,891.6
<b>Total Current Assets</b>	<b>8,918.3</b>	8,194.5
Bank loans	<b>940.7</b>	196.3
Trade payables	<b>791.5</b>	626.7
Accruals and other payables	<b>3,097.5</b>	3,256.0
Lease liabilities	<b>26.0</b>	20.9
Provisions	<b>92.1</b>	86.6
Income tax payable	<b>75.6</b>	67.5
<b>Total Current Liabilities</b>	<b>5,023.4</b>	4,254.0
<b>Net Current Assets</b>	<b>3,894.9</b>	3,940.5

Our net current assets decreased by 1.2% from RMB3,940.5 million as of 31 December 2023 to RMB3,894.9 million as of 31 December 2024, which was mainly due to the decrease in the Company's cash at bank and on hand and the increase in bank loans.

## Adjusted Net Gearing Ratio and Quick Ratio

Our adjusted net gearing ratios (adjusted net debt (interest-bearing debt plus unaccrued proposed dividends) divided by adjusted equity (total equity of the Company less unaccrued proposed dividends)) were 25.5% and 34.9% as of 31 December 2023 and 31 December 2024, respectively.

Our quick ratios (total current assets, excluding inventories, divided by total current liabilities as of the same date) were 1.7 times and 1.6 times as of 31 December 2023 and 31 December 2024, respectively.

## **Trade and Other Receivables**

Trade and other receivables are stated at amortized cost using the effective interest method less allowance for credit losses. As of 31 December 2024, our trade and other receivables (net of bad debt allowance of RMB261.7 million) were RMB5,216.8 million.

## **Trade and Other Payables**

Our trade and other payables mainly consist of trade payables and accruals and other payables, which include receipts in advance, other taxes payables, deposits from promoters, payables to promoters, payables for staff related costs, dividends payables and other accruals and payables. As of 31 December 2024, our trade and other payables were RMB3,889.0 million.

## **Issuance of Bonds**

On 25 October 2024, the Company issued RMB500 million corporate bonds with coupon rate of 2.25% due in 2027 (China Isotope & Radiation Corporation's 2024 Public Offering of Technology Innovation Corporate Bonds to Professional Investors (Phase I)). For details, please refer to the Company's announcements dated 22 October 2024, 23 October 2024 and 25 October 2024.

## **Bank Loans**

As of 31 December 2023 and as of 31 December 2024, the Group's total bank loans amounted to RMB1,570.37 million and RMB1,682.43 million, respectively, and the Group's total loans from CNNC Finance Company Limited amounted to RMB60.03 million and RMB297.01 million, respectively.

## **Capital Expenditures**

Our capital expenditures mainly comprise additions to plant and equipment and intangible assets. In 2024, our capital expenditures were RMB1,044.0 million.

## **Contingent Liabilities**

As of 31 December 2024, we did not have any material contingent liabilities.

## **Foreign Exchange and Exchange Rate Risk**

During the year ended 31 December 2024, the Group's revenue was mainly denominated in RMB, and it was exposed to currency risk through bank deposits denominated in foreign currency, which were primarily Hong Kong dollars. The Group monitors foreign exchange movements and determines exchange when necessary. The Group currently has no foreign exchange hedging policy.

## **Credit Risk**

In order to minimize the credit risk, we have policies in place to monitor the exposures to these credit risks on an ongoing basis. Before accepting any new customer requiring credit over a certain credit amount, we carry out research into their creditability and assess their credit quality and define credit limits for that customer. Our individual credit evaluations focus on the customer's historical payment records, and take into account information specific to the customer as well as pertaining to the economic environment in which the customer operates.

We normally do not require collateral from customers. Therefore, our exposure to credit risk is influenced mainly by the individual characteristics of each customer rather than the industry in which the customer operates. The significant concentration of credit risk primarily arises when we rely heavily on individual customers. We will, however, perform periodic credit evaluation on our customers and monitor the compliance of credit terms by them. We believe we do not have any significant concentration of credit risk as the trade and bill receivables involve a large number of customers across diverse industries and geographical areas.

## **Liquidity Risk**

Our policy is to regularly monitor current and expected liquidity requirements to ensure that we maintain sufficient reserves of cash and adequate commitment funds from major financial institutions to meet both short-term and long-term liquidity requirements. Our Directors believe that there is no significant liquidity risk, as we have sufficient monetary capital to fund our operations.

## **DIVIDEND POLICY**

The dividend policy of the Company is summarized as below:

In distributing the profit after tax of the current year, the Company shall allocate 10% of its profit into its statutory reserve fund. When the aggregate amount of the statutory reserve fund of Company is more than 50% of its registered capital, further appropriations are not required. Where the statutory reserve fund of the Company is insufficient to make up for the losses of the previous year, the profits of the current year shall be used to make up for such losses before making allocation to its statutory reserve fund in accordance with the aforementioned. After allocation of its profits after tax to its statutory reserve fund, the Company may, subject to the approval of the shareholders of the Company at the shareholders' general meeting allocate its profits after tax to its discretionary reserve fund. After making up for the losses and making allocations to the reserve fund, any remaining profits after tax shall be distributed by the Company to the shareholders of the Company in proportion to their respective shareholdings according to the resolution adopted at the shareholders' general meeting of the Company. If the shareholders' general meeting of the Company has, in violation of the provision of the aforementioned, distributed profits to the shareholders of the Company before the Company has made up for its losses and made allocations to its statutory reserve fund, the shareholders of the Company shall return to the Company the profit distributed in violation of the provision. The Company's shares held by the Company are not entitled to any profit distribution.

The Company may distribute dividends in the form of cash or shares.

Dividends are declared and paid in RMB to holders of domestic shares of the Company, whereas dividends payable to holders of H shares will be declared in RMB and payable in Hong Kong dollars. Exchange rate between RMB and Hong Kong dollar will be the arithmetic mean of the median of the exchange rates of Hong Kong dollars against RMB as quoted by the People's Bank of China for the five business days preceding the date of the dividend payment (inclusive). The Company's specific profit distribution proposal will be formulated by the Board in accordance with the relevant laws and regulations and the Company's operating conditions, based on the opinions of the Company's independent Directors, and will be considered and decided by general meeting of the Company. In the event that a profit distribution proposal is approved at the general meeting of the Company, the Company will implement the specific plan within two months after the conclusion of the relevant general meeting.

When the Board recommends the declaration of cash dividends to shareholders of the Company (the "**Shareholder(s)**") at a general meeting, the decision to declare any dividends and the amount of dividends will depend on, among other things:

- our results of operations and cash flows;
- our financial position;
- overall performance;
- our future prospects;
- statutory, regulatory and contractual restrictions on the payment of dividends by us; and
- other factors that the Board deems relevant.

## **NO MATERIAL ADVERSE CHANGE**

The Directors have confirmed that there was no material adverse change in our financial and trading position or prospects as of 31 December 2024.

## **SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD**

Save as disclosed above, there were no significant subsequent events to be disclosed after the Reporting Period to the date of this announcement.

## **USE OF PROCEEDS FROM THE INITIAL PUBLIC OFFERING**

On 6 July 2018, H shares of the Company became listed on the Main Board of the Stock Exchange (stock code: 1763). Based on the offer price of HKD21.60 per H share and upon the partial exercise of the over-allotment option (100 shares), the net proceeds that the Group received from the Global Offering were approximately HKD1,690.0 million after deduction of the underwriting commissions and other estimated expenses in relation to the Global Offering. As at 31 December 2024, current assets of approximately RMB268.1 million were used and approximately RMB536.1 million was used in selective mergers and acquisitions.



The Group has utilised the net proceeds from the Global Offering in accordance with the intended use disclosed in the prospectus of the Company dated 22 June 2018 and the announcements of the Company dated 29 March 2019 and 20 September 2019. In accordance with the requirements of paragraph 11(8) of Appendix D2 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”), the use of proceeds will be updated to provide the use of proceeds from the initial public offering for 2024 (including the expected timeline of full utilisation of the balance), which is set out below:

*RMB in million*

Use	Initial Allocation of the net proceeds	Revised Allocation of the net proceeds	Amount Utilised as of 31 December 2018	Amount Utilised as of 31 December 2019	Amount Utilised as of 31 December 2020	Amount Utilised as of 31 December 2021	Amount Utilised as of 31 December 2022	Amount Utilised as of 31 December 2023	Amount Utilised as of 31 December 2024	Balance as of 31 December 2024	Expected time of full utilisation of balance
Investment in imaging diagnostic and therapeutic radiopharmaceuticals manufacturing and research and development bases	597.3	460.0	0.0	29.5	200.0	251.5	427.0	459.3	460.0	0.0	
Establishment of production and distribution subsidiaries	67.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Establishment of new production facilities	84.5	50.0	0.0	50.0	50.0	50.0	50.0	50.0	50.0	0.0	
Investment in the research and development of various imaging diagnostic and therapeutic radiopharmaceuticals, raw materials of radioactive source products, medical radioisotopes, and UBT products and related raw materials	253.6	118.3	0.0	76.6	101.2	105.4	105.5	105.5	105.5	12.8	In 2025
Investments/selective (mergers) acquisitions	286.5	536.1	51.4	529.9	536.1	536.1	536.1	536.1	536.1	0.0	
Working capital and general corporate purposes	143.3	268.1	71.7	232.5	268.1	268.1	268.1	268.1	268.1	0.0	
Total	<u>1,432.5</u>	<u>1,432.5</u>	<u>123.1</u>	<u>918.5</u>	<u>1,155.4</u>	<u>1,211.1</u>	<u>1,386.7</u>	<u>1,419.0</u>	<u>1,419.7</u>	<u>12.8</u>	

*Note:* The investment in the research and development in the use of proceeds is under preparation due to certain research and development projects to be newly launched. There may be differences between the actual and expected timeline for utilising the proceeds for investment in research and development. The specific timeline of utilisation of the proceeds for the investment in the research and development is subject to the actual timeline of utilisation of the projects. The Company will fulfill the disclosure obligations in accordance with the relevant requirements according to the progress of the projects.

## EMPLOYEES AND REMUNERATION POLICY

The Group had a total of 3,367 (as at 31 December 2023: 3,105) employees as at 31 December 2024. During the year ended 31 December 2024, our staff costs were approximately RMB886.0 million (for the year ended 31 December 2023: RMB867.4 million). The remuneration policy of the Group is to motivate and retain excellent staff so as to realize the long-term enterprise goals and objectives of the Group. The employee remuneration policy of the Group is determined after taking into account the overall salary level in the industry, employees' performance and other factors. The management regularly reviews the employee remuneration policy and arrangement of the Group.

We provide our employees with salaries and bonuses, as well as employee benefits, including employee retirement benefit schemes, medical and vocational injury insurance schemes and housing provident fund schemes. Our employees located in China are covered by the mandatory social security schemes defined by PRC local practice and regulations, which are essentially defined contribution schemes. The Group contributes to the basic pension insurance schemes based on the applicable benchmarks and rates prescribed by government departments, pursuant to which such entities are required to contribute to the schemes at the rate of 16% of the employee's basic salary. Employees of these entities are entitled to retirement benefits calculated as a percentage of the average wage level in China from the above-mentioned retirement plan at the time of their normal retirement. The Group shall not use any forfeited contributions to reduce the level of existing contributions. Details of the Company's fixed contribution plan are set out in note 28(b) to the consolidated financial statements of this annual report. In addition to the government's mandatory basic pension and medical schemes, the Group also provides fixed retirement benefits to retired citizens, current retirees and certain eligible active employees (the "**Plan**"), which has covered 25.74% of the Group's employees as at 31 December 2024. The Plan is managed by the Group and funded by the Group's working capital. Under the Plan, eligible retirees and/or employees are entitled to fixed supplemental post-retirement pension benefits, defined death benefits and supplemental post-retirement medical benefits. There are no Plan assets and therefore no information on the market value, contribution level or material surplus or shortfall of the Plan assets can be disclosed. Details of the Company's defined benefit plan are set out in note 28(a) to the consolidated financial statements.

We provide training to all of our employees to have them equipped with the necessary skills to perform their jobs competently and to give them the opportunities to realize their personal career goals and aspirations. We are also committed to providing individuals with management and leadership training that will improve our capability to achieve our vision, mission and growth objectives. We realize the importance of developing individual career paths that will help employees develop their full potential. Development opportunities are provided as a result of on-the-job training and formal training programs.

We adhere to the market-oriented employment mechanism, and in 2024, we organized the open selection of middle managers at the headquarters and subsidiaries, with the adjustment ratio exceeding 50%, effectively activating the vitality of the cadre team. The annual performance-based salary of the heads of the subsidiaries were rigidly redeemed, and the salary difference between the heads reached 2.4 times in 2023. For the two units that failed the tenure assessment from 2021 to 2023, the annual performance-based salary of the heads during their tenure was zero, and the performance orientation was strengthened.

## HEDGING ACTIVITIES

During the year ended 31 December 2024, the Group had not entered into any hedging transaction in relation to foreign exchange risks or interest rate risks.

## MAJOR ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

On 3 April 2024, the Company and CNNC Hainan Nuclear Power Co., Ltd. (“**CNNC Hainan Nuclear Power**”) jointly invested in the establishment of CNNC (Yulin) Irradiation Co., Ltd., with a registered capital of RMB50 million, of which 51% was contributed by the Company and 49% was contributed by CNNC Hainan Nuclear Power. For details, please refer to the Company’s announcement dated 3 April 2024.

On 16 December 2024, CNGT, CNNC 404 Company Limited, Gansu Runyuan Environmental Resources Technology Co., Ltd. (甘肅潤源環境資源科技有限公司), Jiuquan Economic Development and Investment (Group) Co., Ltd. (酒泉市經濟開發投資(集團)有限責任公司), Jinta Jinxin Industrial Investment and Development Group Co., Ltd. (金塔縣金鑫工業投資發展集團有限公司) and Jiayuguan Urban Development Group Co., Ltd. (嘉峪關市城發集團有限責任公司) jointly invested in the establishment of Gansu Hongye Nuclear Technology Co., Ltd. (甘肅弘業核技術有限公司) (“**Gansu Hongye**”), with a registered capital of RMB95 million, of which 10% was contributed by CNGT. For details, please refer to the Company’s announcements dated 16 December 2024 and 23 December 2024.

Save as disclosed above, the Company did not have any major acquisition or disposal of subsidiaries, associates or joint ventures during the Reporting Period.

## FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

The Group will actively explore investment opportunities in and outside the PRC to diversify its source of income, which may or may not include any acquisition or disposal of assets and/or business by the Group. Any such plans will comply with the applicable requirements under the Listing Rules (where appropriate).

As at the date of this announcement, the Company had no specific future plans to make material investments or acquire capital assets.

## **CORPORATE GOVERNANCE AND OTHER INFORMATION**

### **Compliance with the Corporate Governance Code**

The Company has adopted and applied the principles and provisions of the Corporate Governance Code set out in Appendix C1 to the Listing Rules.

During the Reporting Period, the Company has complied with the mandatory code provisions of the Corporate Governance Code. The Group has always been committed to enhancing its corporate governance level and deems the corporate governance as an integral part of the value created for shareholders of the Company. The Group has, with reference to the code provisions of the Corporate Governance Code set out in Appendix C1 to the Listing Rules, established a modern corporate governance structure effectively balanced and independently operated by the general meeting, the Board, the supervisory committee and senior management of the Company. The Company has also adopted the Corporate Governance Code as the corporate governance practices of the Company.

### **Compliance with the Model Code for Securities Transactions**

The Group has adopted a set of code with the standard no less favorable than that of the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 of the Listing Rules (the “**Customised Code**”) as its own code of conduct regarding securities transaction by all Directors, supervisors (the “**Supervisors**”) and the relevant employees of the Company.

Having made specific enquiry by the Directors and Supervisors, all Directors and Supervisors confirmed that they had complied with the required standards as set out in the Customised Code during the Reporting Period. No incident of non-compliance with the Customised Code by such employees was noted by the Company.

### **Audit and Risk Management Committee**

The audit and risk management committee of the Company (the “**Audit and Risk Management Committee**”) consists of two independent non-executive Directors and one non-executive Director, namely Mr. Poon Chiu Kwok (chairman), Mr. Lu Chuang and Mr. Chen Zan, which terms of reference comply with the Listing Rules.

The Audit and Risk Management Committee has considered and reviewed the accounting principles and practice adopted by the Group and has discussed the relevant internal control and financial reporting matters with the management, including reviewing the consolidated financial results of the Group for the year ended 31 December 2024.

On 26 March 2025, the Audit and Risk Management Committee reviewed and confirmed the annual results announcement of the Group for the year ended 31 December 2024, annual report of 2024 and the consolidated financial information for the year ended 31 December 2024.

## Scope of Work of Auditor

The figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the year ended 31 December 2024 as set out in this preliminary announcement have been agreed by the Group's auditor, SHINEWING (HK) CPA Limited, to the amounts set out in the Group's audited consolidated financial statements for the year. The work performed by SHINEWING (HK) CPA Limited in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by SHINEWING (HK) CPA Limited on this preliminary announcement.

## Purchase, Sale or Redemption of the Listed Securities of the Company

During the year ended 31 December 2024 and as of the date of this announcement, neither the Company nor any of its subsidiaries purchased, sold or redeemed any listed securities (including sale of treasury shares) of the Company.

As at 31 December 2024, neither the Company nor its subsidiaries hold any treasury shares.

## 2024 Annual General Meeting

The 2024 annual general meeting of the Company (the "AGM") will be held on Tuesday, 3 June 2025, and the notice of the AGM will be published on the websites of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.circ.com.cn](http://www.circ.com.cn)) in due course.

## 2024 Final Dividend

The Board resolved to declare a final cash dividend of RMB0.3090 per Share (inclusive of tax) for the year ended 31 December 2024 (the "2024 Final Dividend") to Shareholders whose names appear on the register of members of the Company on 12 June 2025, with a total cash dividend to be distributed of RMB98,841,344.10 (inclusive of tax). The 2024 Final Dividend is expected to be declared and paid in RMB to holders of Domestic Shares and, whereas dividends payable to holders of H shares will be declared in RMB and payable in Hong Kong dollars before 2 August 2025. Exchange rate between RMB and Hong Kong dollar will be the average median price of the exchange rate for Hong Kong dollar to RMB as quoted by the People's Bank of China for the five working days immediately preceding the date of the AGM (inclusive). The above dividend distribution proposal is subject to the review and approval by Shareholders at the AGM. Details of the dividend distribution will be published after the AGM.

According to the "Enterprise Income Tax Law of the People's Republic of China" and its implementing rules, which came into effect on 1 January 2008, and other relevant rules, the Company is required to withhold 10% enterprise income tax before distributing the proposed 2024 Final Dividend to non-resident enterprise Shareholders whose names appear on the register of members of the Company. Any H Shares registered in the name of non-individual registered Shareholders, including but not limited to HKSCC Nominees Limited, other nominees, trustees or other groups and organizations, will be treated as being held by non-resident enterprise Shareholders and therefore will be subject to the withholding of enterprise income tax.

According to the letter titled the “Tax arrangements on dividends paid to Hong Kong residents by mainland companies” issued by the Stock Exchange to the issuers on 4 July 2011 and a circular (Guo Shui Han [2011] No. 348) issued by the State Administration of Taxation on 28 June 2011, and relevant laws and regulations, if individual holders of H Shares are residents of Hong Kong or Macau or countries which have entered into a tax treaty with the PRC stipulating a dividend tax rate of 10%, the Company will withhold and pay individual income tax at the rate of 10% on behalf of such Shareholders. If individual holders of H Shares are residents of countries which have entered into a tax treaty with the PRC stipulating a dividend tax rate of less than 10%, the Company will nonetheless withhold and pay individual income tax at the rate of 10% on behalf of such Shareholders. In such a case, if the relevant Shareholders would like a refund of the additional amount withheld, the Company will apply for the agreed preferential tax treatment provided that information required by the applicable tax treaty notice(s) is submitted to the Company’s H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited. If individual holders of H Shares are residents of countries which have entered into a tax treaty with the PRC stipulating a dividend tax rate of more than 10% but less than 20%, the Company will withhold and pay individual income tax at the actual tax rate stipulated in the relevant tax treaty. If individual holders of H Shares are residents of countries which have entered into a tax treaty with the PRC stipulating a dividend tax rate of 20%, or countries which have not entered into any tax treaty with the PRC, or under any other circumstances, the Company will withhold and pay individual income tax at the rate of 20% on behalf of such Shareholders.

The Company assumes no responsibility and will not entertain any claim arising from any delay in, or inaccurate determination of, the tax status or tax treatment of Shareholders or any dispute over tax(es) withheld. Shareholders are recommended to consult their tax advisers regarding the PRC, Hong Kong and other tax effects involved in their holding and disposal of H Shares.

### **Closure of Register of Members**

The Company will hold the AGM on Tuesday, 3 June 2025. The register of members of the Company will be closed from Wednesday, 28 May 2025 to Tuesday, 3 June 2025 (both dates inclusive) and from Monday, 9 June 2025 to Thursday, 12 June 2025 (both dates inclusive). Shareholders whose names appear on the register of members of the Company on Tuesday, 3 June 2025 will be entitled to attend and vote at the AGM. Shareholders whose names appear on the register of members of the Company on Thursday, 12 June 2025 will be entitled to receive the 2024 Final Dividend. For the purpose of being qualified as Shareholders to attend and vote at the AGM, Shareholders must lodge all transfers documents with the Company’s H Share Registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong (for holders of H Shares) or the Company’s registered office at Room 418, South 4th Floor, Building 1, No. 66 Changwa Middle Street, Haidian District, Beijing, China (for holders of Domestic Shares) for registration no later than 4:30 p.m. on Tuesday, 27 May 2025. For the purpose of being qualified as Shareholders to receive the 2024 Final Dividend (subject to the approval by Shareholders at the AGM), Shareholders must lodge all transfers documents with the Company’s H Share Registrar (see the address above) (for holders of H Shares) or the Company’s registered office (see the address above) (for holders of Domestic Shares) for registration no later than 4:30 p.m. on Friday, 6 June 2025.



## **Publication of Results Announcement and Annual Report**

This announcement has been published on the websites of the Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and the Company ([www.circ.com.cn](http://www.circ.com.cn)). The Company will publish the annual report for the year ended 31 December 2024 on the above websites in due course.

By order of the Board  
**China Isotope & Radiation Corporation**  
**Han Yongjiang**  
*Chairman*

Beijing, the PRC, 28 March 2025

*As at the date of this announcement, the Board comprises Mr. Han Yongjiang, Mr. Zhang Junqi and Ms. Huo Yingying as executive Directors; Mr. Chen Zan, Mr. Ding Jianmin and Ms. Chang Jinyu as non-executive Directors; and Mr. Poon Chiu Kwok, Ms. Chen Jingshan, Mr. Lu Chuang and Mr. An Rui as independent non-executive Directors.*